GSK to license Empirico’s COPD candidate for $85M upfront
ENDPOINTS NEWS—GSK said Tuesday it will spend $85 million upfront for an exclusive license to a Phase 1-stage small interfering RNA (siRNA) product being developed by Empirico to treat COPD.
Empirico will oversee the ongoing Phase 1 study of EMP-012, which a GSK spokesperson said is due to read out next year. After that, GSK will take over clinical development, approval filings and sales worldwide.
The UK pharma could fork over up to $660 million more if EMP-012 meets development, regulatory and commercial goals, plus tiered sales royalties.